Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $31.2 million.

  • Rocket Pharmaceuticals' Total Current Liabilities fell 2203.6% to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.2 million, marking a year-over-year decrease of 2203.6%. This contributed to the annual value of $40.7 million for FY2024, which is 1612.41% down from last year.
  • Rocket Pharmaceuticals' Total Current Liabilities amounted to $31.2 million in Q3 2025, which was down 2203.6% from $43.4 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Total Current Liabilities peaked at $48.5 million during Q4 2023, and registered a low of $22.2 million during Q4 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Total Current Liabilities had a median value of $33.5 million in 2023 and averaged $33.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 9177.8% in 2021, then tumbled by 4426.06% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Total Current Liabilities (Quarter) stood at $22.2 million in 2021, then skyrocketed by 76.7% to $39.2 million in 2022, then grew by 23.84% to $48.5 million in 2023, then decreased by 16.12% to $40.7 million in 2024, then dropped by 23.39% to $31.2 million in 2025.
  • Its last three reported values are $31.2 million in Q3 2025, $43.4 million for Q2 2025, and $35.3 million during Q1 2025.